Methods for determining genetic predisposition to autoimmune diseases by genotyping apoptotic genes
Patent 6162604 Issued on December 19, 2000. Estimated Expiration Date: 
April 1, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
April 1, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorApplicationNo. 283040 filed on 04/01/1999US Classes:435/6, Involving nucleic acid435/91.2, Acellular exponential or geometric amplification (e.g., PCR, etc.)536/24.31, Probes for detection of animal nucleotide sequences536/24.33PrimersExaminersPrimary: Fredman, JeffreyAssistant: Chakrabarti, Arun Kr. Attorney, Agent or FirmInternational ClassesC12Q 001/68C12P 019/34 C07H 021/04 AbstractGenetic markers associated with programmed cell death were characterized and their extent of polymorphism in normal populations was determined allowing for a method for determining genetic predisposition to SLE and other autoimmune diseases by genotyping. The allelic distribution of these gene markers in a large Mexican American SLE cohort and ethnically matched controls was determined. The results were that bcl-2, Fas-L, and IL-10 loci showed significantly different allelic distribution in SLE patients compared with controls, indicating an association between these gens and SLE. The method allows for determining the presence of these alleles. Alone, the presence of each of these alleles is associated with a moderate increase in SLE risk, while the occurrence of these alles together increases the odds of developing SLE by more than 40-fold.Other References
|
| ||||||||||||||
